- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
Novo Nordisk A/S R&D Investor Call Transcript
A warm welcome to Novo Nordisk investor and analyst event here at the ADA this year in San Diego, and also a warm welcome to those of you listening to the webcast. So my name is Daniel, and I'm heading up Investor Relations here at Novo Nordisk.
So we'll start this session by a presentation, and then we'll have a Q&A afterwards. And as always, I need to remind you that there might be forward-looking statements in what we're going through.
This is our strategic aspirations we defined back in 2019, and we report on them on a quarterly basis. You see here the highlights for the first quarter of this year. And we continue to make progress on all our aspirations. Within purpose and sustainability, so ESG, we made progress on all our aspirations, but I will only highlight that we now treat more than 37 million people living with diabetes. That is also reflected in our diabetes value market share, which we increased, and we are now at more than 32%, in line with our -- tracking well on our aspiration of achieving more than 1/3 of the diabetes market in 2025.
Sales growth
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |